Lower Level Of Innovation Could Undermine Expedited Approval Pathways
Executive Summary
A Health Affairs study notes that the rate of serious post-marketing safety concerns has risen while PDUFA has pushed down drug review times, feeding into concerns about the increasing use of expedited approvals.
You may also be interested in...
Medical Advances Get More Chances When Safety Issues Arise
Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.
Rx Post-Approval Duration Of Use Is Not Indicator Of Safety – FDA Editorial
The postmarketing safety of prescription drugs cannot be predicted using specific time markers following approval, FDA Office of Medical Policy Director Robert Temple, MD, maintained in an editorial in the May 1 Journal of the American Medical Association
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.